recent
year
seen
unpreced
invest
research
develop
countermeasur
highthreat
pathogen
includ
specif
ambiti
object
develop
diagnost
therapeut
vaccin
inadequ
avail
biolog
refer
materi
pathogen
pose
genuin
obstacl
pursuit
object
lack
comprehens
equit
framework
develop
refer
materi
weak
outlin
need
intern
standard
biolog
materi
highthreat
pathogen
core
element
global
health
secur
also
outlin
key
compon
framework
address
defici
although
sever
hundr
center
contribut
collabor
studi
center
produc
hold
irp
center
nation
institut
biolog
standard
control
england
center
biolog
evalu
research
unit
state
paulehrlich
institut
germani
role
institut
produc
store
distribut
irp
differ
distribut
repositori
materi
us
center
diseas
control
prevent
intern
reagent
resourc
nation
institut
allergi
infecti
diseas
biodefens
emerg
infect
research
resourc
repositori
aftermath
west
africa
ebola
viru
diseas
evd
outbreak
consider
focu
expedit
research
develop
ensur
better
prepar
futur
diseas
outbreak
launch
research
develop
blueprint
action
prevent
epidem
global
strategi
prepared
plan
seek
build
upon
success
address
gap
identifi
evd
outbreak
focus
sever
emerg
diseas
potenti
creat
public
health
emerg
inadequ
treatment
prevent
option
current
avail
blueprint
organ
oper
fall
cluster
activ
improv
coordin
acceler
research
develop
process
develop
norm
standard
streamlin
oper
research
develop
respons
outbreak
furthermor
second
cluster
focus
acceler
research
develop
process
subdivid
distinct
area
work
assess
epidem
threat
defin
prioriti
pathogen
develop
research
develop
roadmap
acceler
evalu
diagnost
therapeut
vaccin
outlin
appropri
regulatori
ethic
pathway
central
research
develop
blueprint
list
prioriti
diseas
first
publish
novemb
subsequ
revis
tailor
priorit
method
tabl
prioriti
diseas
list
research
develop
roadmap
produc
encompass
diagnost
vaccin
therapeut
first
research
develop
roadmap
develop
publish
middl
east
respiratori
syndrom
coronaviru
merscov
serv
inform
roadmap
gener
process
diseas
prioriti
pathogen
list
within
merscov
roadmap
develop
refer
reagent
identifi
prioriti
major
oper
ethic
issu
associ
sourc
obtain
bulk
start
materi
reagent
discuss
alli
initi
coalit
epidem
prepared
innov
cepi
whose
aim
acceler
develop
vaccin
highthreat
pathogen
necess
refer
materi
develop
evalu
new
diagnost
vaccin
biotherapeut
recogn
cepi
format
work
group
standard
assay
explicitli
consid
research
develop
blueprint
evd
epidem
irp
exist
diseas
research
develop
bueprint
expedit
develop
led
product
interim
ebola
antibodi
refer
reagent
octob
first
intern
standard
endors
octob
although
acceler
product
repres
impress
collabor
feat
lack
avail
pcr
antigen
antibodi
irp
start
evd
outbreak
subsequ
outbreak
infect
merscov
zika
viru
like
hamper
develop
accur
diagnost
vaccin
addit
except
circumst
unpreced
durat
evd
epidem
enabl
major
proport
irp
develop
occur
outbreak
ongo
develop
irp
sampl
acquisit
endors
usual
take
year
consider
longer
outbreak
diseas
research
develop
blueprint
avail
irp
often
rare
sporad
diseas
epidem
potenti
soon
occurr
outbreak
would
facilit
diagnost
research
activ
seroepidemiolog
studi
immunogen
assess
experiment
vaccin
present
time
except
zair
ebolaviru
antibodi
antigen
nucleic
acid
extens
character
follow
intern
collabor
studi
enabl
activ
biolog
prepar
express
way
global
commonli
intern
unit
intern
refer
reagent
less
extens
character
intern
standard
assign
intern
unit
refer
reagent
interim
intend
replac
expir
deplet
group
refer
materi
establish
collect
aid
evalu
assay
diagnost
test
compli
requir
refer
standardsreag
work
secondari
standard
refer
standard
establish
region
nation
author
laboratori
calibr
traceabl
primari
materi
intend
use
routin
test
world
health
organ
irp
whoendors
zika
viru
rna
antibodi
standard
irp
exist
diseas
research
develop
blueprint
avail
irp
diseas
would
facilit
develop
essenti
tool
epidem
prepared
includ
diagnost
vaccin
therapeut
accur
access
diagnost
tool
vital
limit
public
health
effect
diseas
outbreak
addit
provid
reliabl
data
clinic
epidemiolog
studi
coordin
diagnost
product
develop
effort
epidem
diseas
threat
initi
foundat
innov
new
diagnost
auspic
cepi
initi
seek
build
collabor
key
diagnost
partner
enabl
adequ
provis
diagnost
capabl
outbreak
state
irp
major
resourc
ensur
reliabl
vitro
biolog
diagnost
procedur
use
diagnosi
diseas
recent
epidem
caus
merscov
ebola
viru
zika
viru
highlight
complex
prompt
develop
sensit
specif
assay
particularli
would
access
resourc
constrain
set
avail
intern
refer
standard
encompass
genet
materi
antigen
antibodi
would
enabl
harmon
calibr
test
standard
would
facilit
develop
valid
diagnost
assay
includ
nucleic
acid
amplif
test
serolog
assay
antigenbas
pointofcar
test
vaccin
therapeut
current
licens
regul
europ
unit
state
use
diseas
research
develop
blueprint
august
declar
ebola
outbreak
west
africa
public
health
emerg
intern
concern
declar
led
subsequ
concert
effort
intern
scientif
commun
acceler
develop
ebola
vaccin
fund
regulatori
ethic
review
expert
advic
manufactur
support
initi
extraordinari
speed
although
vaccin
develop
consid
rel
success
compon
ebola
research
develop
effort
recombin
vesicular
stomat
viruszair
ebola
viru
show
high
efficaci
ring
vaccin
trial
develop
came
late
major
effect
cours
west
africa
epidem
candid
vaccin
also
underw
clinic
evalu
encourag
safeti
immunogen
data
gener
phase
trial
sever
candid
howev
studi
perform
differ
group
varieti
immunogen
assay
refer
reagent
use
make
comparison
immunogen
result
complic
set
biolog
standard
common
assay
would
enabl
calibr
harmon
assay
data
trial
could
prove
vital
determin
correl
protect
clinic
outcom
standard
would
also
enabl
better
select
candid
vaccin
transit
preclin
stage
clinic
evalu
consider
interest
biolog
therapi
emerg
epidem
threat
convalescentphas
plasma
monoclon
antibodi
evalu
treatment
ebola
consid
therapi
zika
viru
merscov
form
key
focu
merscov
research
develop
blueprint
roadmap
avail
diseas
identifi
next
review
use
blueprint
decis
instrument
includ
list
irp
would
enabl
character
potenc
puriti
ident
complex
biolog
materi
antibodi
would
facilit
research
immunotherapi
also
standard
prepar
postlicensur
antigen
nucleic
acid
refer
materi
synthes
recombin
techniqu
long
necessari
genom
sequenc
data
avail
newli
emerg
pathogen
acquisit
live
pathogen
might
requir
simpl
blood
draw
complic
field
oper
midst
epidem
logist
issu
regard
process
storag
acut
potenti
infecti
sampl
also
present
mani
obstacl
howev
ideal
start
materi
product
antibodybas
refer
prepar
serum
plasma
convalescentphas
patient
novel
method
gener
fulli
human
immunoglobulin
use
refer
materi
explor
human
plasma
readili
avail
inocul
transchromosom
cattl
subsequ
isol
antibodi
howev
technolog
still
rel
new
convalescentphas
serum
consid
superior
close
repres
clinic
sampl
polyclon
rang
antibodi
specif
optim
pool
sampl
although
mani
previou
clinic
studi
research
develop
blueprint
prioriti
diseas
result
collect
storag
plasma
convalesc
patient
sever
obstacl
would
larg
preclud
sampl
repurpos
gener
refer
materi
issu
includ
sampl
volum
receipt
appropri
consent
appropri
record
document
sampl
proven
willing
research
share
sampl
suitabl
altern
repurpos
old
sampl
would
initi
clinic
studi
object
includ
acquisit
blood
sampl
product
refer
materi
research
develop
blueprint
prioriti
diseas
howev
studi
would
sever
challeng
mani
pathogen
prioriti
pathogen
list
caus
outbreak
difficult
anticip
tempor
geograph
outbreak
often
limit
number
case
durat
factor
complic
prospect
acquisit
appropri
clinic
sampl
develop
refer
materi
addit
pathogen
commonli
caus
outbreak
resourceconstrain
environ
poor
healthcar
infrastructur
limit
diagnost
capabl
suboptim
diseas
report
system
would
limit
retrospect
identif
suitabl
patient
develop
ebola
antibodi
irp
plasma
obtain
either
recov
evd
patient
sierra
leon
enrol
convalescentphas
plasma
trial
donat
countri
directli
involv
outbreak
itali
norway
unit
kingdom
unit
state
howev
would
inappropri
use
exampl
model
sampl
acquisit
requir
occurr
larg
devast
outbreak
concert
intern
respons
success
focus
effort
obtain
materi
gener
irp
made
highthreat
epidem
diseas
method
identifi
sampl
patient
previou
outbreak
explor
addit
prepar
promptli
identifi
sampl
patient
prospect
given
diagnosi
futur
outbreak
made
prepar
would
optim
likelihood
obtain
highqual
sampl
rare
sporad
diseas
pathogen
nipah
viru
rift
valley
fever
viru
would
requir
systemat
coordin
approach
bring
togeth
local
investig
intern
partner
transpar
equit
framework
global
initi
intern
sever
acut
respiratori
emerg
infect
consortium
exist
facilit
rapid
respons
emerg
infecti
diseas
epidem
threat
aid
share
clinic
research
tool
openaccess
clinic
studi
protocol
initi
consortium
would
well
place
bring
togeth
intern
partner
coordin
collabor
framework
outlin
process
acquisit
sampl
gener
refer
materi
preemptiv
identif
studi
site
prepar
studi
document
includ
templat
protocol
clinic
agreement
detail
method
identifi
recruit
potenti
donor
sampl
collect
process
role
respons
would
optim
likelihood
success
regard
situat
access
exist
sampl
appropri
consent
use
refer
prepar
unavail
process
acquir
new
sampl
develop
refer
materi
regist
uniqu
studi
priorit
epidem
diseas
process
would
requir
ethic
approv
sought
appropri
channel
thu
enabl
appropri
scrutini
relev
ethic
regulatori
bodi
countri
coordin
activ
diseaseendem
countri
sampl
collect
countri
intern
partner
studi
would
involv
minim
risk
particip
would
involv
administr
investig
medicin
product
instanc
singl
venesect
would
requir
serum
plasma
plasmaderiv
product
contain
insuffici
genet
materi
univers
consid
human
tissu
legisl
howev
must
consid
human
biolog
materi
therefor
inform
consent
indispens
requir
donat
donor
receiv
inform
concern
aspect
studi
emphasi
place
fact
particip
entir
voluntari
intend
use
blood
compon
gener
storag
intern
distribut
refer
materi
must
explain
addit
potenti
beneficiari
procedur
involv
appropri
measur
also
taken
ensur
protect
person
data
confidenti
issu
must
explain
donor
inform
contain
detail
particip
inform
sheet
provid
donor
advanc
provid
consent
consent
process
consist
particip
sign
date
inform
consent
form
studyspecif
procedur
perform
collabor
intern
framework
could
includ
templat
particip
inform
sheet
inform
consent
form
could
readili
adapt
diseaseand
countryspecif
studi
appropri
share
biolog
materi
necess
rapid
research
progress
recent
experi
epidem
highlight
concert
effort
establish
accept
process
obtain
share
refer
materi
need
present
time
small
number
institut
manufactur
provid
refer
materi
use
irp
therefor
export
sampl
institut
essenti
step
product
irp
epidem
diseas
initi
exist
facilit
share
benefit
aris
use
access
human
nonhuman
genet
materi
exampl
initi
pandem
influenza
prepared
pip
framework
launch
pip
framework
seek
address
concern
lowand
middleincom
countri
share
influenza
viru
specimen
match
assur
benefit
deriv
share
would
equit
distribut
concern
inequit
share
benefit
exacerb
influenza
pandem
unequ
access
vaccin
despit
exampl
set
pip
framework
recent
epidem
infecti
diseas
continu
rais
issu
regard
sampl
share
exampl
local
export
restrict
brazil
prevent
share
wellcharacter
sampl
recent
zika
viru
epidem
therebi
present
obstacl
rapid
develop
assess
diagnost
gener
guidanc
fair
equit
share
benefit
aris
use
genet
biolog
resourc
nagoya
protocol
protocol
supplementari
agreement
convent
biolog
divers
contain
detail
guidanc
divid
follow
object
access
oblig
benefit
share
oblig
complianc
oblig
similar
guidanc
exist
plasmaderiv
product
antibodi
refer
materi
howev
mani
facet
nagoya
protocol
would
remain
pertin
plasmaderiv
product
could
adapt
inform
procedur
accept
humanderiv
product
object
commerci
sourc
profit
enshrin
sever
key
document
would
continu
appli
develop
irp
distribut
irp
either
free
charg
nation
control
laboratori
small
handl
charg
ship
cost
organ
negoti
relev
parti
preemptiv
interact
research
donor
countri
author
could
lead
clearli
defin
mutual
agre
upon
process
acquisit
export
sampl
process
could
subsequ
specifi
legal
bind
clinic
studi
agreement
thu
ensur
complianc
principl
equit
benefit
share
provid
solut
complex
issu
intellectu
properti
product
ownership
access
right
irp
diseas
research
develop
blueprint
prioriti
diseas
list
caus
categori
pathogen
handl
potenti
infecti
materi
often
requir
biosafeti
level
laboratori
recent
year
threat
bioterror
result
strict
rule
requir
us
feder
select
agent
regul
result
increas
cost
limit
research
reduc
collabor
institut
howev
encourag
increas
number
biosafeti
level
laboratori
global
initi
exist
seek
harmon
practic
facilit
collabor
laboratori
ultim
goal
posit
contribut
global
health
safe
acquisit
process
export
import
sampl
recov
emerg
highthreat
diseas
patient
would
requir
care
plan
requir
would
base
natur
histori
specif
diseas
studi
site
patient
characterist
period
convalesc
sinc
acut
ill
liaison
nation
author
donor
recipi
countri
regard
export
import
regul
requir
would
necessari
addit
diseas
occur
primarili
lowand
middleincom
countri
often
remot
rural
set
access
accur
medic
record
diagnost
tool
limit
clear
specif
regard
method
diagnosi
patient
clinic
detail
diseas
cours
sampl
collect
date
storag
detail
would
requir
biolog
irp
infecti
diseas
epidem
potenti
major
global
asset
support
time
effici
develop
vaccin
therapeut
diagnost
critic
barrier
develop
refer
materi
epidem
infect
acquisit
suitabl
sourc
materi
highlight
seri
key
issu
need
address
systemat
framework
accept
parti
work
begin
develop
agre
framework
gener
irp
diseas
drug
diagnost
vaccin
avail
futur
outbreak
dr
rampl
infecti
diseas
clinician
academ
clinic
fellow
hospit
tropic
diseas
univers
colleg
london
london
uk
research
interest
virolog
epidem
prepared
clinic
evalu
vaccin
